January 8 - 11, 2018
Hard Rock Hotel
San Diego, California, USA
Abstract submission deadline: Tuesday, October 31
Advance registration deadline: Monday, November 27
Monday, Jan. 8
Tuesday, Jan. 9
Wednesday, Jan. 10
Thursday, Jan. 11
Monday, Jan. 8
Welcome Remarks and Opening Keynote Lectures 6-8 p.m.
Welcome RemarksFred R. Hirsch, CEO, IASLC
Immunotherapy in lung cancer: The good, the bad, and the uglyMatthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, New York
The role of aneuploidy during tumorigenesisTeresa Davoli, Harvard Medical School, Boston, Massachusetts
Functional lung cancer genomics through in vivo genome editing Monte M. Winslow, Stanford University School of Medicine, Stanford, California
Opening Reception8-10 p.m.
Continental Breakfast and Networking Roundtables7-8 a.m.
Plenary Session 1: Early Steps in Lung Oncogenesis 8-10 a.m.
Elucidating lung stem cells and the initiation of lung cancer at single-cell resolutionMark A. Krasnow, Stanford University, Stanford, California
Early steps in lung oncogenesisSamuel Janes, University College London, London, United Kingdom
Molecular mechanisms of lung cancer development: between metabolic reprogramming and genomic instability in the field of cancerizationPierre P. Massion, Vanderbilt University Medical Center, Nashville, Tennessee
Influence of cancer initiation on tumor progression in SCLCJulien Sage, Stanford University School of Medicine, Stanford, California
Modeling Rb loss and pathway reactivation in lung adenocarcinoma*David M. Feldser, University of Pennsylvania, Philadelphia, Pennsylvania
Plenary Session 2: Early Detection 10:30 a.m.-12:25 p.m.
Individualized risk-based lung cancer screening: The way forwardChristine D. Berg, National Cancer Institute, Bethesda, Maryland
Inflammation and immunity in pulmonary premalignancySteven M. Dubinett, David Geffen School of Medicine at UCLA, Los Angeles, California
Intercepting lung cancer via the airway transcriptomeAvrum E. Spira, Boston University School of Medicine, Boston, Massachusetts
Gene networks, airway smoke injury, and cancer riskBruce A.J. Ponder, Cancer Research UK Cambridge Research Institute, Cambridge, United Kingdom
Diagnostic and prognostic utility of urinary creatine riboside for early stage non-small cell lung cancer*Takahiro Oike, National Cancer Institute, Besthesda, Maryland
Poster A Highlights Session12:25-12:35 p.m.
Poster Session A / Lunch12:40-2 p.m.
Plenary Session 3: Liquid Biopsies2:30-3:45 p.m.
Early detection of molecular residual disease in localized lung cancer via circulating tumor DNA profilingMaximilian Diehn, Stanford University, Stanford, California
Circulating tumor DNA in early-stage NSCLC: A lung TRACERx studyChristopher Abbosh, University College London Cancer Institute, London, United Kingdom
ctDNA assessment of resistance and heterogeneity in EGFR mutant lung cancersZofia Piotrowska, Partners Cancer Care/MGH Cancer Center, Boston, Massachusetts
Plenary Session 4: Heterogeneity and Evolution4-6:15 p.m.
Liquid biopsies and lung cancer evolutionTrever G. Bivona, University of California San Francisco, San Francisco, California
Tracking Lung Cancer Evolution through therapy-(TRACERx): Immune evasion, progression and adaptationCharles Swanton, The Francis Crick Institute and University College London Cancer Institute, London, United Kingdom
Evolution of acquired resistance in EGFR-mutant NSCLCAaron N. Hata, Massachusetts General Hospital, Charlestown, Massachusetts
Cell-of-origin footprints in lung cancer genomes and transcriptomesMarcin Imielinski, Weill Cornell Medical College, New York, New York
Dissecting the playbook of cancer: Genomic analysis of 100,000 human tumors reveals elaborate patterns of activation of the RTK-RAS-MAPK pathway*Gerard Manning, Genentech, South San Francisco, California
Decoding tumor microenvironment to enhance NSCLC targeted therapy*Haichuan Hu, MGH Cancer Center/Harvard Medical School, Charlestown, Massachusetts
Evening on Own6:15 p.m.-
Top of page
Continental Breakfast7-8 a.m.
Plenary Session 5: Immunotherapy: Biomarkers and Checkpoint Blockade in NSCLC8-10 a.m.
Immunotherapy: Biomarkers and checkpoint blockade in NSCLCDavid P. Carbone, Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Mechanisms of acquired resistance to immune checkpoint inhibitors in lung cancerKaterina A. Politi, Yale University Cancer Center, New Haven, Connecticut
Immunotherapy for thoracic malignancies beyond NSCLCSolange Peters, Centre Cordonne D'Oncologie - CHUV, Lausanne, Switzerland
Safety and activity of the IL-15/sIL-15Rα complex ALT-803 in combination with the anti-PD1 mAb nivolumab in metastatic non-small cell lung cancer*John Wrangle, Medical University of South Carolina, Charleston, South Carolina
Investigating ectopic lymphoid aggregates in a genetically engineered mouse model of lung adenocarcinoma*Kelli Connolly, Yale University, New Haven, Connecticut
Role of the microbiota in inflammation and lung cancer*Ana I. Robles, National Cancer Institute, Besthesda, Maryland
Plenary Session 6: Vaccines, Cellular Therapy, Neoantigen Targeting10:30 a.m.-11:20 a.m.
Allele-specific HLA loss and immune escape in lung cancer evolutionRachel Rosenthal, University College London, London, United Kingdom
12 p.m.-1:30 p.m.
Plenary Session 7: Small Cell Lung Cancer1:30-3:40 p.m.
Mechanisms of chemoresistance in SCLCCharles M. Rudin, Memorial Sloan Kettering Cancer Center, New York, New York
MYC drives molecular and therapeutically distinct subtype of SCLCTrudy G. Oliver, University of Utah Huntsman Cancer Institute, Salt Lake City, Utah
The genomic landscape of SCLC and other neuroendocrine lung tumorsJulie George, University of Cologne, Cologne, Germany
Circulating Tumor Cells: A liquid biopsy for SCLC with multiple applicationsCaroline Dive, Cancer Research UK Manchester Institute, Manchester, UK
Functional characterization and evolutionary reconstruction of small cell lung cancer transformation of EGFR-mutant lung adenocarcinomas*June-Koo Lee, Harvard Medical School, Boston, Massachusetts
Alterations in cell junctions and neuroendocrine differentiation are key early steps in Crebbp/Ep300 mutation-driven SCLC development*Kwon-Sik Park, University of Virginia, Charlottesville, Virginia
Plenary Session 8: Imaging, Radiation Oncology, Radiomics4-5:30 p.m.
ImmunoPET imaging of DLL3 in small cell lung cancerJohn T. Poirier, Memorial Sloan Kettering Cancer Center, New York, New York
Radiation therapy in lung cancer: Recent trends and future directionsDaniel R. Gomez, The University of Texas MD Anderson Cancer Center, Houston, Texas
Multiscale modeling of lung cancerOlivier Gevaert, Stanford University, Stanford, California
Multimodality imaging of human lung squamous cell carcinoma reveals unique metabolic dependencies that are effectively targeted with metabolic based therapies*David B. Shackelford, UCLA David Geffen School of Medicine, Los Angeles, California
Poster Session B Highlights5:30-5:40 p.m.
Poster Session B / Reception5:40-7 p.m.
Evening on Own7 p.m.-
Plenary Session 9: Tumor Microenvironment8-10 a.m.
Comprehensive enumeration of immune cells in the tumor microenvironment using multiplexed ion beam imagingMichael Angelo, Stanford University School of Medicine, Stanford, California
Targeting cellular heterogeneity in lung adenocarcinomaTuomas Tammela, Memorial Sloan Kettering Cancer Center, New York, New York
Immune contexture evolution during lung cancer carcinogenesis and its potential clinical implicationsJianjun Zhang, The University of Texas MD Anderson Cancer Center, Houston, Texas
Regulatory T cells, polymorphisms, and response to checkpoint blockade: From mechanisms to potential biomarkersSergio Quezada, University College London Cancer Institute, London, United Kingdom
Hyperspectral imaging tools capture the spatial organization of cell subsets within the tumour microenvironment*Katey S.S. Enfield, British Columbia Cancer Research Center, Vancouver, BC, Canada
Plenary Session 10: Targeted Therapies10:15 a.m.-12 p.m.
Precise inhibition of oncogenic BRAF activationZhan Yao, Memorial Sloan Kettering Cancer Center, New York, New York
A combined protein-protein interaction and genetic interaction map defines new and critical Kras effectors in non-small cell lung cancer*Peter K. Jackson, Stanford University School of Medicine, Stanford, California
Progress and unanswered questions in EGFR mutation–positive lung cancerLecia Sequist, Massachusetts General Hospital, Boston, Massachusetts
MET copy number gain is associated with gefitinib resistance in leptomeningeal carcinomatosis of EGFR-mutant lung cancer*Shigeki Nanjo, University of California San Francisco, San Francisco, California
The art in the science of ALK positive lung cancer managementTony S.K. Mok, Chinese University of Hong Kong, Shatin, Hong Kong
*Short talk from proffered abstract